LUP Statistics
Record
- Title
- Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
- Type
- Journal Article
- Publ. year
- 2015
- Author/s
- Gimsing, P; Hjertner, Ø; Abildgaard, N; Andersen, N F et al.
- Department/s
- Division of Hematology and Clinical Immunology
- In LUP since
- 2016-04-01
Downloads
| Total | This Year | This Month |
| 332 | 3 | 1 |
United States of America  |
167 (50%) |
Germany  |
112 (34%) |
France  |
8 (2%) |
China  |
8 (2%) |
Russian Federation  |
5 (2%) |
Singapore  |
5 (2%) |
Canada  |
3 (1%) |
Ireland  |
3 (1%) |
Netherlands (Kingdom of the)  |
3 (1%) |
United Kingdom of Great Britain and Northern Ireland  |
3 (1%) |
Sweden  |
2 (1%) |
Bulgaria  |
2 (1%) |
India  |
2 (1%) |
Italy  |
1 (0%) |
Czechia  |
1 (0%) |
Taiwan (China)  |
1 (0%) |
Hong Kong (China)  |
1 (0%) |
Turkiye  |
1 (0%) |
Nigeria  |
1 (0%) |
New Zealand  |
1 (0%) |
South Korea  |
1 (0%) |